Insider Cluster (2 insiders) ·Filed Mar 13, 2026

CNTA

Centessa Pharmaceuticals plc
BEARISH
Impact 7/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $4.4M total
Actionable Insight ▼ Bearish

Monitor for upcoming earnings or pipeline updates; such concentrated C-suite selling often precedes negative news or reflects valuation concerns. Watch for follow-on selling or lack of buybacks.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
CNTA ▲ +50.78% at T+60d
SHORT call ✗ call lost -50.78% · α vs SPY -39.16% · entry $26.33 → $39.70
Entry anchored
Mar 12, 03:59 PM ET
via exchange tick
T+1d
+7.44%
call -7.44% · α -6.42%
$28.29
settled 7mo ago
T+5d
+2.77%
call -2.77% · α -4.89%
$27.06
settled 7mo ago
T+20d
+50.28%
call -50.28% · α -46.70%
$39.57
settled 6mo ago
T+60d
+50.78%
call -50.78% · α -39.16%
$39.70
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Centessa Pharmaceuticals C-suite executives sold over $7.2M in stock within a week, primarily from Chief People Officer Karen Anderson's open-market sales of 215,922 shares. These sales followed derivative exercises and represent a material insider divestment.

Key Financial Metrics

Direction
selling
Total Value
$7.2M
Insiders
2

Key Facts

  • Chief People Officer Karen Anderson sold 215,922 shares for $5.65M in open-market transactions at ~$26.15 per share
  • Anderson also exercised derivatives for 407,244 shares (some at $4.01, others at $0), with total economic value of $816,524.22
  • Chief Business Officer Gregory Weinhoff sold 61,253 shares for $1.6M
  • Total open-market sales by insiders: $7.25M over 7 days
  • Total insider sales represent ~0.19% of $3.8B market cap — significant for a biotech

Financial Impact

$7.25M in open-market insider selling, representing 0.19% of market cap

insider sentimentshareholder dilution riskmarket confidence

Risk Factors

  • Insider selling may signal lack of confidence in near-term prospects
  • Biotech stocks are sensitive to sentiment; this level of selling could pressure share price

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (7 trades, 7d window)cluster-CNTA-1773699014839
5 reports for CNTA
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+20▲ +0.33%Apr 17, 2026
Filters
Rows
Reports for CNTA — sortable, filterable
TypeNow
Jul 6, 2026
12w ago
15-12G
BEARISH ★ 7/10
—awaiting T+20——
Apr 17, 2026
24w ago
PREM14A
BULLISH ★ 9/10
$39.51 $39.64▲ +0.33%▼ −3.87%—
Apr 13, 2026
24w ago
DEFA14A
BULLISH ★ 8/10
$39.59 $39.59· 0.00%▼ −6.30%—
Mar 13, 2026
29w ago
Insider Cluster
BEARISH ★ 7/10
$26.33 $39.57▼ −50.28%▼ −46.70%—
Mar 13, 2026
29w ago
Insider Cluster
BEARISH ★ 6/10
$26.33 $39.57▼ −50.28%▼ −46.70%—
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (64h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 16, 2026